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Enhancing Natural Killer and CD81 T Cell-Mediated
Anticancer Cytotoxicity and Proliferation of CD81 T Cells
with HLA-E Monospecific Monoclonal Antibodies
Mepur H. Ravindranath,1 Edward J Filippone,2 Asokan Devarajan,3 and Shahab Asgharzadeh4
Cytotoxic NK/CD81 T cells interact with MHC-I ligands on tumor cells through either activating or inhibiting
receptors. One of the inhibitory receptors is CD94/NKG2A. The NK/CD81 T cell cytotoxic capability is lost
when tumor-associated human leukocyte antigen, HLA-E, binds the CD94/NKG2A receptor, resulting in tumor
progression and reduced survival. Failure of cancer patients to respond to natural killer (NK) cell therapies
could be due to HLA-E overexpression in tumor tissues. Preventing the inhibitory receptor–ligand interaction by
either receptor- or ligand-specific monoclonal antibodies (mAbs) is an innovative passive immunotherapeutic
strategy for cancer. Since receptors and ligands can be monomeric or homo- or heterodimeric proteins, the efficacy
of mAbs may rely on their ability to distinguish monospecific (private) functional epitopes from nonfunctional
common (public) epitopes. We developed monospecific anti-HLA-E mAbs (e.g., TFL-033) that recognize only
HLA-E-specific epitopes, but not epitopes shared with other HLA class-I loci as occurs with currently available
polyreactive anti-HLA-E mAbs. Interestingly the amino acid sequences in the a1 and a2 helices of HLA-E, critical
for the recognition of the mAb TFL-033, are strikingly the same sequences recognized by the CD94/NKG2A
inhibitory receptors on NK/CD81 cells. Such monospecific mAbs can block the CD94/NKG2A interaction with
HLA-E to restore NK cell and CD81 anticancer cell cytotoxicity. Furthermore, the HLA-E monospecific mAbs
significantly promoted the proliferation of the CD42/CD81 T cells. These monospecific mAbs are also invaluable
for the specific demonstration of HLA-E on tumor biopsies, potentially indicating those tumors most likely to
respond to such therapy. Thus, they can be used to enhance passive immunotherapy once phased preclinical studies
and clinical trials are completed. On principle, we postulate that NK cell passive immunotherapy should capitalize
on both of these features of monospecific HLA-E mAbs, that is, the specific determination HLA-E expression on a
particular tumor and the enhancement of NK cell/CD81 cytotoxicity if HLA-E positive.
Keywords: human leukocyte antigen, monospecific versus polyreactive, monoclonal antibody, natural killer
receptors, single antigen bead assay, mean fluorescent intensity
Introduction
A ctive specific and passive immunotherapies of hu-man cancers aim to reprogram the metabolic profile of
the tumors and their microenvironment during the progres-
sion of cancers. There is a need to identify and detect the
specific biomarkers of the metabolic profile of a tumor or an
immune cell on an individual patient basis. Biomarkers,
whether composed of proteins or polysaccharides or lipids,
can be monomeric, homodimeric, or heterodimeric. Mono-
clonal antibodies (mAbs) are indeed the most valuable tools
for their specific immunodiagnosis. Furthermore, biomarkers
may contain common (public or shared) epitopes in addition
to specific and individual or unique epitopes. Therefore, it is
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critical to examine whether a mAb is genuinely monospecific
for a biomarker, by demonstrating reaction only with private
epitopes as opposed to shared epitopes.
Although cellular immunotherapy has successfully ex-
plored antitumor CD81 T cell responses, it is increasingly
realized that human cancers reprogram by developing strat-
egies to escape T cell recognition. Counter strategies are
needed to upregulate killer T cells as well as manipulate
natural killer (NK) cells to attack the cancer cells. The NK
cells share expression of cell surface antigens and effector
molecules, such as CD2, CD7, CD90, perforin, granzyme A,
and interferon-c, with T lymphocytes on one hand, and the
surface antigens such as CD11b and CD11c with myeloid
cells on the other, based on specific genes required for T cell
receptor (TCR) rearrangement.(1) The 112 genes for cell
surface and signaling receptors and molecules are found to be
significantly upregulated in NK cells,(2) and such upregula-
tion may exhibit both inter- and intraindividual variations
during various stages of tumorigenesis, metastasis, and in-
fections. Therefore, personalized therapy should precisely
monitor these variations in the molecular expression of such
biomarkers. Indeed, precise monitoring requires well-defined
and precise tools.
The NK cell receptors of the immunoglobulin (Ig) super-
family (e.g., killer cell Ig-like receptors, also known as KIRs
and Ig-like transcripts) recognize human major histocom-
patibility complex (MHC) class-I molecules (human leuko-
cyte antigens [HLAs] -Ia, -Ib, and MICA/MICB).(3–6) Some
of these receptors transmit activating signals, whereas others
mediate inhibition. One major class of genes controlling both
activating and inhibitory NK cell receptor groups (NKGs) is
Klrc1 [NKG2A], Klrc2 [NKG2C], and Klrk1 [NKG2D] and
are involved in specific interactions with the MHC of tumor
cells and virally infected cells. Each NKG2 subunit is a type
II glycoprotein belonging to the C-type lectin superfam-
ily, with an extracellular domain with transmembrane and
cytoplasmic segments. The analogous murine Ly49 family
receptors(5) and human KIR(3,4) both bind to cell surface
HLA-Ia molecules on target cells. Natural killer cell group 2
(NKG2) receptors interact specifically with HLA-Ib and
MICA/MICB as the homodimer (NKG2D) or as hetero-
dimers (NKG2A, NKG2C), and such interactions are highly
conserved across species. Most of the NKG2 isoforms
(NKG2A, B, C, E, and H, but not NKG2D) form disulfide-
linked heterodimers with an invariant chain, CD94.(7,8)
NKG2A and NKG2B, which are alternatively spliced
products from a single gene, have two immunoreceptor
tyrosine-based inhibitory motifs in their cytoplasmic do-
mains and form inhibitory receptors when complexed with
CD94.(2,7) The specific ligands for CD94/NKG2A/C het-
erodimers are identified as nonclassical class-I molecules
(HLA-Ib) in humans.(8–10)
The homodimer NKG2D interacts with MICA
on tumor cell surface
NKG2D is a unique activating receptor of NK cells that
share little similarity with the other isoforms of NKG2 re-
ceptors and does not associate with CD94. The receptor is on
natural killer T cells (NKT) cells, subsets of gd T cells,(2)
activated macrophages,(11) and naive human CD8+ T cells.
CD4+T cells can be induced to express it under certain
pathological conditions, such as Crohn’s disease, juvenile-
onset lupus, and cytomegalovirus infection.(12) NKG2D
recognizes highly polymorphic MHC loci MICA (60 allelic
variants) and MICB (30 allelic variants), also known as
‘‘stress-induced MHC’’ on normal cells,(13,14) tumor,(15) and
virally infected cells.(16) NKG2D–MICA interaction leads to
tumor cell destruction, mediated by the release of perforin by
the NK and other immune cells.(11) NKG2D is also to rec-
ognize other protein ligands, encoded by genes that encode
functional proteins [in square brackets] in humans (RAET1E
[ULBP4], RAET1G [ULBP5], RAET1H [ULBP2], RAET1I
[ULBP1], RAET1L [ULBP6], and RAET1N [ULBP3]).(17)
The interaction of the activating NK cell receptor NKG2D
with tumor cell surface MICA and MICB has been exten-
sively studied(18–29) in gastrointestinal (GI) epithelium and
several epithelial tumors. The extracellular transport of
MICA and MICB is independent of the general peptide
processing machinery that is required for the assembly of
peptides for other antigen-presenting HLA-I molecules.(13–
18) The MICA/B proteins share *30% identical amino acid
residues throughout a1, a2, and a3 domains with other HLA
class-I proteins. They possess seven to eight N-linked gly-
cosylation sites, unique transmembrane and cytoplasmic tail
sequences, and three extra cysteine residues in the a1 and a3
domains. Unlike HLA class-I proteins, they do not dimerize
with b2-microglobulin (b2m).
Tumor cells may escape NKG2D–MICA-mediated im-
mune attack by disulfide–isomerase-enabled proteolytic de-
grading and shedding of MICA.(18) Ferrari de Andrade
et al.(19) have designed antibodies targeting the MICA a3
domain, the site of proteolytic cleavage for shedding, and
found that these antibodies prevented loss of cell surface
MICA and MICB in human cancer cells. Interestingly, these
antibodies do not inhibit binding of the a1 and a2 domains
with receptors and allowed continued NKG2D–MICA in-
teractions to inhibit murine tumor progression in mouse
models and reduced human melanoma metastases in a hu-
manized mouse model. However, in some cancers at the
advanced stage, the expression of ligands for NKG2D may
promote tumor progression rather than regression. A recent
report documents NKG2D activation-mediated tumor pro-
gression in a model of inflammation-driven liver cancer,(20)
with the critical differentiating factor purported to be the
surrounding inflammation. Hence, the nature of the micro-
environment within and surrounding tumors may have the
potential of altering the impact of NKG2D activation, and
this aspect deserves attention while studying the impact of
NKG2D interaction with MICA and other such ligands on the
tumor cell surface.
In recent years, NKG2D–MICA ligand interactions in
different cancers have been reviewed extensively.(21–25) The
crystal structure of MICA shows restructured a1 and a2 he-
lices, the regions interacting with NKG2D, and there is al-
tered folding with a shallow remnant of a peptide-binding
groove without a peptide.(26–28) The interaction between
deglycosylated recombinant MICA and NKG2D shows that
the NKG2D can bind to the presumptive peptide grooves of
a1 and a2 domains at the top of the MICA platform, analo-
gous to abTCR recognition of MHC class-I proteins.(29)
Since there are 60 allelic variants of MICA proteins, re-
markable variations may occur in the a1 and a2 domains
affecting binding of NKG2D with the MICA alleles.(30)
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However, it is also suggested that the NKG2D binding sites
are on the underside of the MICA a1 and a2 domains, this
region is comparable with the cryptic domain in classical
and nonclassical HLA-I proteins masked by b2m. This
domain in classical and nonclassical HLA-I loci contains
mostly shared or public epitopes.(31)
Cancer-Associated HLA Class-I Molecules
and NKG2A/CD94
As noted previously, NKG2 receptors different from
NKG2D may mediate NK suppression of tumor killing rather
than activation. Earlier studies reported that NK cells can kill
autologous and allogeneic tumor cells without involving the
MHC.(32) Lymphomas deficient in MHC antigens were re-
jected in vivo in contrast to MHC-expressing lymphomas.(33)
Such loss of MHC expression failed to activate inhibitory
NKG2 receptors (other than the activating NKG2D).
Similarly, Liao et al.(34) observed that the normal T cell
blasts from MHC-I-deficient mutant mice are effectively
targeted by NK cells in vitro, a finding that supports the
speculation that HLA class-I expressed on regular T cell
blasts may result in inhibition of NK-mediated cell killing.
Furthermore, an inverse correlation was noted between
in vitro NK-mediated cytolysis and the level of target cell
HLA class-I expression.(35) However, no such correlation
was noticed with target cell HLA class-II molecules.(35)
Moretta et al.(36) have studied the interaction between the
CD94 receptor and HLA class-I. The cells expressed HLA-
B7 protected target cells from NK lysis. The protection was
abolished by CD94-specific mAbs (XA-185) but not by the
mAbs conjugated with the soluble CD94 molecule. The
CD94-specific mAbs (XA-185) did not react with the inhib-
itory NKG2A receptor, as it failed to stain COS-7 cell lines
(fibroblast-like cell lines) transfected only with NKG2A but
stained those transfected with both CD94 and NKG2A. In
contrast, yet another mAb Z199, which does not recognize
CD94, strongly reacted with COS cells cotransfected with
CD94/NKG2A,(37) suggesting the occurrence of hetero-
dimerization of NKG2A with CD94. Contrastingly, the same
group documented the inhibitory role of CD94/NKG2A in a
predominantly CD8+ fraction of human T lymphocytes.(38) In
the presence of IL-15, the CD8+ T cells expressed CD94 de
novo. CD94 expression commenced 4–6 days after addition
of IL-15. Both CD4+ and CD8+ cells expressed CD94, but the
simultaneous expression of NKG2A occurred only with
CD8+ cells. Similar data were obtained in T cell populations
activated in mixed lymphocyte cultures in the presence of
IL-15. The expression of CD94/NKG2A diminished the
allospecific cytolytic activity by mixed lymphocyte culture-
derived T cell populations. Importantly, the cytolysis was
reinstated by adding anti-CD94 mAbs, which masks the
inhibitory NK cell CD94. These and similar observations(39)
confirmed that the binding of CD94/NKG2A with HLA
class-I on tumor cells protected them from cytotoxic killing
by both NK cells and a subset of CD8+ T cells, although the
precise mechanism remained to be clarified.
Tumor-Associated HLA-E as the Specific Ligand
for CD94/NKG2A
HLA class-I molecules include highly polymorphic clas-
sical HLA class-Ia (HLA-A, -B, and -C alleles) and the least
polymorphic nonclassical HLA class-Ib (HLA-E, -F, or -G).
Literature increasingly documents that HLA-E may function
as the specific ligand for the inhibitory NKG2 receptors. The
fundamental structure of HLA-E is not much different from
any one of the HLA class-Ia molecules (Fig. 1A). Interest-
ingly, the HLA-E heavy chain shares several amino acid
sequences with HLA class-Ia, despite several unique differ-
ences in the amino acid sequences or epitopes between HLA-
E and HLA-Ia alleles (Tables 1 and 2). HLA-E functions by
assembling with the leader peptide of HLA class-Ia/-Ib pro-
teins as its cognate peptide.(40) The leader peptide is loaded at
the N terminus of the newly synthesized HLA class-I mole-
cule. The role of leader peptide is to ensure translocation of
the newly synthesized HLA class-I heavy chain into the en-
doplasmic reticulum (ER) and promote the transportation of
the HLA across the ER. Upon completion of the task, the
leader peptide is cleaved from the heavy chain of HLA by a
signal peptidase(41) and enters the cytoplasm. From there, the
leader peptide itself must be transported across the ER
membrane, which requires regular transporter associated
with antigen processing (TAP) expression and function.
Normal maturation and insertion of HLA-E into the cell
surface membrane requires the leader peptide of HLA class-I
molecules or leader peptides of HLA-F or HLA-G (but not
the leader peptide of HLA-E itself) to bind the HLA-E pep-
tide grove in the ER. A newly synthesized HLA-E matures
and forms a stable complex only in the presence of the leader
peptide of most HLA-A, -B, -C, and -G molecules, but not its
own leader peptide.(40)
HLA-E is expressed at the cell surface only if a suitable
leader peptide from specific class-Ia or class-Ib alleles (other
than HLA-E itself) associates as the cognate peptide of a
complete HLA trimer. Some viral peptides (Table 3) can also
fulfill this function. These leader peptides should be present
in the ER at sufficient levels to ensure expression of a sig-
nificant amount of trimeric HLA-E on the cell surface. Thus
HLA-E is highly evolved to bind specifically to the class-I
leader peptide.(41) The class-I leader peptide or microbial
(cytomegalovirus, human immunodeficiency virus, Hep-C,
and others) peptides may not be available when tumor cells
and virally infected cells have downregulated HLA-I ex-
pression.(42) Furthermore, viruses can inhibit the function of
TAP(43,44), which is required to transport leader peptides, and
cleaved from nascent class-I molecules, from the cytoplasm
into the ER. Under these circumstances, intact HLA-E may
not be expressed on the cell surface, permitting NK lysis of
the tumor cell or virally infected cell.(41)
Two independent groups(10,45) have validated the finding
that HLA-E functions as the specific ligand for CD94/
NKG2A receptors. The absence of binding between CD94/
NKG2A and classical HLA-Ia molecules was confirmed(46)
by the direct binding of the soluble receptor and functional
assays with CD94/NKG2A-positive NK cells. Braud et al.(10)
constructed in vitro the phycoerythrin-labeled biotinylated
tetrameric complexes of the heavy chain of HLA-E and b2m
with a synthetic peptide (VMAPRTVLL) derived from the
signal sequence shared by HLA-B allelic proteins. The pe-
ripheral blood mononuclear cells from nine regular donors
stained for the HLA-E tetramer. An HLA-A2 tetramer with
an Epstein–Barr virus peptide was used as a negative control.
The HLA-E tetramer bound to 2%–11% of lymphocytes from
different individuals, whereas the HLA-A2 tetramer bound
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to 0% and 0.8% of the lymphocytes. On average, an HLA-E
tetramer bound to *57% (varied from 35% to 83% among
individuals) of CD3-/CD56+ NK cells, while the HLA-E
tetramers bound to 12%–60% of CD3+ T cells (some were
CD56+). Most importantly, the HLA-E tetramer did not bind
to the lymphocytes when the cells were pretreated with the
anti-CD94 mAb HP3D9. The interaction between HLA-E
tetramers and CD94 was further confirmed by staining a
number of well-characterized CD94+ NK-cell clones with
HLA-E tetramers and demonstrating that another anti-CD94
mAb DX22 completely abolished this binding. The HLA-A2
tetramer failed to stain the CD94+ NK cell clones.
Lee et al.(45) provided further experimental proof for the
functional dynamics of the interaction between HLA-E and
the NK inhibitory receptors CD94/NKG2A. The validity of
their observation is based upon using two different HLA-I-
deficient LCL 721.221 target cells, one expressing cyto-
plasmic but not cell surface HLA-E (HLA-E*0101 allele),
and the other, LCL.221-AEH cells, that do express cell sur-
face HLA-E (HLA-E*0101 allele). Besides, they used
LCL 721.221 cells transfected with HLA-B*0702, B*2705,
C*0401, C*0302, and B*5101 as controls. Using an effector
NK cell line (CD94/NKG2A positive but negative for Ig
superfamily or killer cell receptor), the effects of the presence
or absence of HLA-E on the surface of LCL721.221 cells
were examined. NK cell-mediated cytolysis was inhibited
only when HLA-E was present on the surface of the target
cells (LCL.221-AEH) but not when it is cytoplasmic (LCL
721.221). Total restoration of lysis was observed after the
addition of various mAbs, including anti-HLA-E ‘‘specific’’
mAb 3D12 (IgG1), pan-HLA-I mAb HP-1F7 (IgG1), anti-
CD94 mAb HP-3B1 (IgG2a), or anti-CD94/NKG2a mAb
(Z199, IgG2b), but not with IgG1 negative control mAb. The
results confirm that the inhibition of lysis was specific both
for HLA-E, because protection was reversed by the 3D12
mAb, and for the CD94/NKG2A complex, because cyto-
toxicity was reconstituted by CD94 (HP-3B1) or CD94/
NKG2A (Z199)-specific mAbs.
FIG. 1. The structure of the nonclassical (HLA class-Ib) human leukocyte antigen HLA-E. (A) The structural orientation
of the three a-helices of the heavy chain with b2m is illustrated. The peptide in the groove is not shown for the purpose of
indicating the location of the specific amino acid sequences or epitopes on the a1 and a2 helices, which serve as the ligand
for monospecific anti-HLA-E mAbs and CD94 and NKG2a receptors on the cell surface of NK cells and CD8+ T cells. The
sequences in yellow in (A–C) are the specific sites of the ligand for mAb TFL-033, assessed based on dosimetric peptide inhibition
studies. (A)The structure of intact or native HLA-E showing epitopes (the specific amino acid sequences) that inhibit the binding of
mAb TFL-033 to HLA-E coated on the beads. The sequences RSARDTA at a1 and SEQKSNDASE at a2 are the TFL-033 binding
regions established based on the peptide-inhibition study.(54) (B, C)The structure of the amino acids in thea1 and a2 helices that are
recognized by CD94 and NKG2A. The letters H, Salt, and vf refer to the sites of hydrogen bonding, salt linkages, and van der Wall
forces between CD94 and NG2A with the a1 and a2 helices, respectively. Gray of amino acid sequences refers to the sequences of
the leader peptide sequence attached to the groove. The attachment of the peptide on the groove renders stability to dimerization of
HLA-E heavy chains and b2m. Theoretically if a mAb binds anywhere in the yellow regions on the a1 and a2 helices, it would
block the binding of the inhibitory receptor of NK cells. This is the basis for the hypothesis that monospecific anti-HLA-E mAbs
define the potential of the mAb to avert the interaction between inhibitory receptors and HLA-E, and thereby preventing the
‘‘inaction’’ or ‘‘switching off’’ of the NK cell function that would otherwise enable tumor cell escape. The boxes refer to the exact
amino acids in HLA-E sequences that interact or bind with the amino acids of CD94 and NKG2A. The linkgage types are shown in
letters below the boxes. b2m, b2-microglobulin; HLA, human leukocyte antigen; mAb, monoclonal antibody; NK, natural killer;
NKG2, natural killer cell group 2.
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Table 1. Gene Sequence-Based (First Row of Numbers) and Secreted Heavy Chain-Based Amino Acid
Sequences (Second Row of Numbers) of Nonclassical HLA-Ib, HLA-E Showing Private (Monospecific)
and Public (Polyspecific) Epitopes in Boxes
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
M V D Q T L L L L L S E A L A L T Q
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
T W A Q S H S L K Y F H T S V S R P
37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Q R G E P R F I S V G Y V D D T Q F
55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72
34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51
V R F D N D A A S P R M V P R A P W
73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69
M E Q E G S E Y W D R E T R S A R D
91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108
70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87
T A Q I F R V N L R T L R G Y N Q S
109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126
88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
S E A Q S H T L Q W M H G C E L G P
127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144
106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123
D R R F L R G Y E Q F A Y D G K D Y
145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162
124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141
L T L N E D L R S W T A V D T A A Q
163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180
142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159
I S E Q K S N D A S E A E H Q R A Y
181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198
160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177
L E D T C V E W L H K Y L E K G K E
199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216
178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195
T L L H L E P P K T H V T H H P I S
217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234
196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213
D H E A T L R C W A L G F Y P A E I
235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252
214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231
T L T W Q Q D G E G H T Q D T E L V
253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270
232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249
E T R P A G D G T F Q K W A A V V V
271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288
250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267
P S G E E G R Y T C H V Q H E G L P
289 290 291 292 293 294 205 296 297 298 299 300 301 302 303 304 305 306
268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285
E P V T L R W K P A S Q P T I P I V
307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324
286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303
G I I A G L V L G S V V S G A V V A
325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342
304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 318 320 321
A A V I W R K K S S G G K G G S Y S
343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358
322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337
K A E W S D S A Q Q S E S H S L
Gene sequences (first row) 1 to 21 is the leader sequence.
The boxes containing monospecific epitopes are marked in italics.
GenBank ARB084481. Norman PJ, Norberg SJ, Guethlein LA, Nemat-Gorgani N, Ronaghi M, and Parham P. DB source: Accession
KY49735. Submitted January 20, 2017.
HLA, human leukocyte antigen.
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The results confirm the importance of HLA-E but highlight
the fact that mAbs binding can abrogate the binding of NK-
associated CD94/NKG2A to the extent of restoring the cy-
tolytic capabilities of the NK cells. The observations had
potential merit since a specific cell line devoid of HLA-I but
incorporated explicitly with cell surface HLA-E was used.
However, it is neither established whether the mAb 3D12 is
capable of binding to the amino acid ligands of CD94/
NKG2A nor whether mAb 3D12 is monospecific for the two
well-known alleles of HLA-E (HLA-EG107 and HLA-ER107).
Such in-depth analysis of monospecificity of anti-HLA-E
mAbs is a prerequisite for using of anti-HLA-E mAbs for
passive immunotherapy either in a preclinical model or for
human trials.
We examined(47) the HLA-I binding affinity of mAb 3D12
using the Luminex single antigen bead (SAB) assay with
beads coated with 30 HLA-A, 50 HLA-B, 16 HLA-Cw, 2
HLA-E, 1 HLA-F, and a couple of HLA-G alleles. We found
that the mAb 3D12 recognized not only HLA-E but also
several HLA-Ia alleles; hence, that the mAb 3D12 is not
specific for HLA-E. Therefore, a mAb that is monospecific
for HLA-E and at the same time capable of binding to the
amino acid ligands of CD94/NKG2A on the HLA-E mole-
cule will be potentially useful to restore cytotoxic killing of
tumor cells as well as for the specific recognition of tumor
cells expressing HLA-E on the cell surface, potentially being
amenable to such therapy.
Specific Amino Acids on a1 and a2 Helices
of HLA-E as Ligands for CD94/NKG2A
The disulfide-liked CD94/NKG2A dimers ‘‘sit across’’ the
peptide-bound cleft of carboxy-terminal end of HLA-E,
precisely interacting with a1 and a2 helices of HLA-E, re-
spectively, as shown in Figure 1A. Petrie et al.(48) have
critically analyzed the electrostatic surfaces of HLA-E, car-
rying the leader sequence peptide of HLA-G namely
VMAPRTLFL in the a1 and a2 helical groove and CD94-
NKG2A. They showed that a basic region on the a1 helix of
HLA-E interacted with an acidic domain on CD94 and,
contrariwise, an acidic region on the HLA-E a2 helix docked
with a basic domain on NKG2A. This study is restricted to the
leader sequence peptide of HLA-G (residues 3–11). How-
ever, several other leader peptides sequences of HLA-Ia are
known to bind to the a1 and a2 helical groove of HLA-E
(Table 3). Whether the strength of acid–base interaction of
NKRs and HLA-E remains the same for all these leader
peptides is not clear at present, although it is assumed to be
similar. However, although all HLA-I leader sequence pep-
tides tested bound to HLA-E and were recognized by CD94/
NKG2A, amino acid variations in the leader sequences af-
fected the stability of HLA-E. It appears that CD94/NKG2A
recognition of HLA-E is controlled by the degree of stabili-
zation of peptide with HLA-E and their cell surface expres-
sion, and both HLA-E heavy chain and cognate peptide form
the ligand for CD94/NKG2A. However, a comparison of the
CD94/NKG2A–HLA-E VMAPRTLFL complex with the
Table 2. Amino Acid Sequences (Epitopes) Shared with Classical HLA-Ia Loci (HLA-A, HLA-B, HAL-Cw,
and Nonclassical HLA-Ib Loci (HLA-F and HLA-G)
HLA-E peptide sequences No. of amino acids
HLA-I alleles
Specificity
Classical Ia Nonclassical Ib
A B Cw F G
47PRAPWMEQE55 9 1 0 0 0 0 A*3306
59EYWDRETR65 8 5 0 0 0 0 A-restricted
65RSARDTA71 (*) 6 0 0 0 0 0 E-restricted
90AGSHTLQW97 8 1 10 48 0 0 Polyspecific
108RFLRGYE123 7 24 0 0 0 0 A-restricted
115QFAYDGKDY123 9 1 194 75 0 0 Polyspecific
117AYDGKDY123 7 491 831 271 21 30 Polyspecific
126LNEDLRSWTA135 10 239 210 261 21 30 Polyspecific
137DTAAQI142 6 0 824 248 0 30 Polyspecific
137DTAAQIS143 7 0 52 4 0 30 Polyspecific
143SEQKSNDASE152(*) 10 0 0 0 0 0 E-restricted
157RAYLED162 6 0 1 0 0 0 B*8201
163TCVEWL168 6 282 206 200 0 30 Polyspecific
182EPPKTHVT190 8 0 0 19 0 0 C-restricted
HLA-E-restricted epitopes are shown in bold italics with (*).
Table 3. Sources of Peptides and Their Sequences
Presented by HLA-E During Interaction
with CD94/NKG2






CMV UL40 VMAPRTLIL (82)
VMAPRTLVL
Hepatitis C virus YLLPRRGPRL (83)
ABC MRP7 ALALVRMLI (84)
HIV p24 AISPRTLNA (85)
Sequences: A, alanine; F, phenylalanine; G, glycine; I, isoleucine;
L, leucine; M, methionine; N, asparagine; P, proline; S, serine; R,
arginine; T, threonine; tyrosine; V, valine.
CMV, cytomegalovirus; NKG2, natural killer cell group 2.
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unligated CD94-NKG2A(49) and HLA-E(50) revealed no
significant conformational change in either HLA-E or CD94-
NKG2A upon complex formation.
According to Petrie et al.,(48) the ‘‘lock and key’’ en-
gagement between HLA-E VMAPRTLFL and CD94-NKG2A
exemplified the ‘‘innate characteristic’’ of this interaction. The
binding of CD94-NKG2A heterodimer with HLA-E involves
8 salt linkages and 19 H bonds (Table 4 and Fig. 1B, C).
Besides, several van der Wall interactions are found between
the heterodimer and the HLA-E (Table 4). CD94 shows greater
association with a1 helix than NKG2a with the a2 helix. The
CD94-NKG2a ‘‘footprints’’ on HLA-E was further confirmed
by studying structural data, and mutating the amino acids of
CD94, NKG2a, and HLA-E involved in the binding.
The interaction between the structures of the CD94-
NKG2A and HLA-EVMAPRTLIL was compared with
the abTCR–HLA-E complex(51) and that of NKG2D–
MICA.(20,23) The position of the CD94-NKG2A footprint on
HLA-E was like that HLA-E–restricted TCR (KK50.4);
however, in the KK50.4TCR interaction with HLA-E, both
heavy chains of the TCR were involved equally in the
binding. Similarly, the proximity of the a1 and a2 helices of
MICA enabled each chain of NKG2D homodimer to interact
with both helices.(13,23) While comparing the HLA-E binding
of the inhibitory receptor CD94-NKG2A with activating
receptors CD94-NKG2C, differences in the binding affini-
ties were observed. Both NKG2A and NKG2C show re-
markable sequence differences and the binding affinity of
NKG2C with HLA-E is found to be much lower than that of
NKG2A.(50,52,53) All these studies fundamentally clarify a
critical aspect of HLA-E function, namely that there are
HLA-E-specific epitopes involved in the interaction with NK
or TCRs, most importantly the HLA-E-specific amino acid
sequences found in the a1 and a2 helices of HLA-E. Table 4
compares the unique amino acid sequences of HLA-E-
specific epitopes with other HLA class-I molecules.
Background and the Central Hypothesis
HLA class-I molecules, which includes HLA-E, are het-
erodimers consisting of a heavy chain polypeptide with b2-
b2m with or without a peptide in the grove. The heavy chains
consist of a1, a2, and a3 helices. It is well known that HLA
class-I loci include HLA-A, (with 3913 alleles and 2747
proteins), HLA-B (4765 alleles and 3465 proteins), HLA-Cw
(3510 alleles and 2450 proteins), and least polymorphic
HLA-E, HLA-F, and HLA-G. The genes are located on
chromosome 6 (6p21.31). The heavy chain of HLA-I shares
several commonly shared amino acid sequences (epitopes)
and a very few specific amino acid sequences. Several shared
sequences are cryptic in the heavy chain due to hetero-
dimerization with b2m. When a trimeric HLA used as an
immunogen either in animal models or when used as autol-
ogous or allogenic vaccines in patients, the shed immunogen
rarely remains intact during immune recognition. Both the
shed heavy chain and the b2m are recognized independently.
Consequently, upon immunizing HLA-E heavy chain in
three mice, we obtained 258 mAbs. Although most of them
were recognized as shared sequences and polyreactive, 31
mAbs were monospecific.(54) We hypothesize that only the
monospecific anti-HLA-E mAbs that are monospecific for
HLA-E are not only useful for specific recognition of HLA-E
on tumor cells and tissues but also can serve to prevent tumor
escape from NIK cell killing by blocking by the interaction of
the inhibitory NK cell CD94-NKG2A with tumor expressed
HLA-E. It is critical and essential that the therapeutic anti-
HLA-E mAbs generated should recognize unique HLA-E-
restricted epitopes but no other epitopes are public and shared
by other HLA-Ia or HLA-Ib molecules.
Polyreactive HLA-E mAbs
Table 5 summarizes the literature on the commercial anti-
HLA-E mAbs used for identification of HLA-E on normal
and tumor tissues, and on tissues were monitored during tu-
mor progression and metastasis. However, the commercial
mAbs such as MEM-E/02, MEM-E/06, MEM-E/07, and
MEM-E/08,(55–60) 3D12,(61) and others listed in Table 5
failed to comply with the stringent criteria of monospecificity
for HLA-E, based on the binding of these mAbs to other HLA
class-I antigens. This finding is well illustrated in Table 6,
which shows how the most commonly used anti-HLA-E mAb
MEM-E/02 and mAb 3D12 react with HLA-A, HLA-B, and
HLA-Cw molecules coated on a solid matrix in the form of
SABs. Each bead is coated with one of the following HLA
molecules: 31 HLA-A, 50 HLA-B, and 16 HLA-Cw. Two
essential and specific publications(47,62) on these two mAbs
clarify the notable findings in greater detail. The possible
epitopes recognized by MEM-E/02 were tested at 1/1200 di-
lution of the mAb and by dosimetric peptide inhibition.(47)
Since MEM-E/02 bound to several HLA-I molecules, we have
selected the epitope present in the heavy chain of HLA-E,
Table 4. Amino Acid Interactions Between
NKG2A/CD94 and HLA-E with Leader
Peptide from HLA-G
HLA-E a1 HLA-E a1 HLA-E a2




Ser77 =Arg65 Ser77 =Arg65 Arg137 = Ser151
Gln112 =Glu152 Gln112 = Ile73 Lys217 =Asp162
Gln113 =Asp69 Gln113 =Asp65
Ser143 =Arg79 Gln113 =Asp69 Salt linkage
Thr146 =Glu89 Phe114 =Glu72 Arg137 = Ser151




Ala161 =Arg79 Thr146 =Glu89 van der Waal
contacts
Glu164 =Gln72 Phe147 =Arg79 Arg137 = Ser151
Glu168 =Glu19 Asn160 =Val76 Arg137 =Glu154
Arg171 =Arg65 Asn160 =Arg79 Lys164 =Arg65
Ala161 =Val76 Pro171 =His155
Salt linkage Ala161 =Arg79 Ser172 =His155
Asp163 =Arg75 Leu162 =Gln72 Lys199 =Asp162
Arg171 =Asp69 Leu162 =Arg75 Gln212 =Ala158
Leu162 =Val76 Gln212 =Glu154
Asp163 =Arg75 Val213 =His155
Glu164 =Glu19 Lys217 =Asp162
Glu164 =Gln72 Lys217 =Ala158
Asn170 =Gln72 Ser223 =Arg131
Arg171 =Arg65 Ser224 =Arg131
Modified from Petrie et al.(48)
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which are most commonly shared by several HLA-I molecules,
as summarized in Table 2. They are 115QFAYDGKDY123,
137DTAAQI,142, and 126LNEDLRSWTA135. Interestingly,
these shared peptides remain cryptic in intact trimeric native
HLA-I (Fig. 2A), but will be exposed in b2m-free HLA heavy
chain (Fig. 2B), well recognized as open conformers. Figure 2
illustrated in a prior publication(47) showed that the binding of
MEM-E/02 to the HLA-Ia molecules coated on the LABSc-
reen HLA-Ia SAB beadsets{ is selectively inhibited by two
of the shared peptides (DTAAQI [48%] and QFAYDGKDY
[24%]) (Fig. 2C, D), but not inhibited by another commonly
shared peptide (LNEDLRSWTA), which served as a potential
control representing a shared but noninhibitory peptide. The
inhibition is further confirmed by dosimetic analysis as shown
in Figure 4 of the report.(47) Recently, Tremante et al.(60) tested
the HLA-I binding of MEM-E/02 on Western blots using the
purified heavy chains (NP40 lysates) from the cell lines that
express HLA-A*11:01, HLA-B*35, HLA-Cw*04:01 (CJO),
Cw*05:01 (221 C5), and HLA-Cw*07:01(221 C7).(60) Indeed,
MEM-E/02 bound to A*11:01, B*35, Cw*04:01, Cw*05:01,
and Cw*07:01 as shown in our report.(47) However, the authors
contended that the MEM-E/02 binding to HLA-Ia antigens on
Western blots is not as intense as the staining of HLA-E heavy
chains. We have also reported(47) that MEM-E/06, E/07 and
E/08 were also cross-reactive to several other HLA class-I
molecules and hence none of the MEM categories of mAbs are
HLA-E monospecific.
Most interestingly, none of these MEM series antibodies
bound to HLA-I antigens coated on a modified version of the
regular beads called iBeads. The regular beadsets provided
for the Luminex assay by the manufacturer (One Lambda,
Inc., Canoga Park, CA) are coated not only with intact tri-
meric HLA class-I molecules but also contain free a-heavy
chains of HLA class-I without b2m and/or the cognate pep-
tide(63) (Fig. 2B). Realizing the existence of the monomeric
and dimeric HLA-I variants in addition to intact trimeric
HLA molecules on the beadsets, the manufacturer developed
iBeads, provided as felix beads for in-house (at Terasaki
Foundation Laboratory [TFL]) experimental use. Although
the iBeads have been well investigated in clinical laborato-
ries(63–70) and proven to be specific for containing only intact
trimeric HLA-I molecules (Fig. 2A), their commercial pro-
duction was abandoned as it was not cost-effective for
commercial use. The iBeads carried only the intact trimeric
HLA. These iBeads are produced by proprietary enzymatic
treatment of regular HLA-Ia antigen coated microbeads to
remove or reduce the amount of free heavy chains (also re-
ferred to as ‘‘denatured antigens’’) by the manufacturers.
Most interestingly, the mAb MEM-E/02 failed to bind to any
one of the HLA molecules coated on the 97 different iBeads
carrying HLA class-I alleles. This finding suggests that
MEM-E/02 is not capable of reacting to intact cell surface
HLA-E or HLA class-I molecules (Fig. 2A), but binds only to
the heavy chain open conformers lacking association with
b2m and/or peptide (Fig. 2B). We have further examined this
issue with another mAb3D12,(62) considered to be specific
for HLA-E,(61) by measuring the mean fluorescence intensity
(MFI) with regular SABs. The results showed that 3D12
simulated MEM-E/02 in recognizing several HLA-B and
HLA-C antigens. As observed with MEM-E/02, binding of
3D12 to HLA-E is inhibited by the public peptide sequences
QFAYDGKDY and DTAAQI, shared by other class-Ia and
class-Ib antigens. Furthermore, a decrease in binding of mAb
3D12 to HLA class-Ia SABs after heat treatment supports the
contention that the epitope is located at the outside of the
‘‘thermodynamically stable’’ a-helix conformations of HLA-
E. Therefore, we emphasize that reliable immunodiagnosis of
HLA-E on histopathological studies on tissues, mainly de-
rived from cancer patients, require proof of monospecificity
of the mAb for HLA-E, by the dosimetric inhibition of the
HLA-E mAbs with one or more of the HLA-E monospecific
epitopes listed in Tables 1 and 2.
Table 5. Documention Cell Surface Expression
of HLA-E on Human Cancers: Monoclonal
Antibodies Used Include MEM-E/02, MEM-E/06,
MEM-E/07, MEM-E/08, 3D12, 3H2679, and TFL-033
mAbs used Cancer types
MEM-E/02 Melanoma(86)







































{HLA antigens representing various alleles on the HLA-Ia
beadset are listed on the One Lambda website under ‘‘Antibody
Detection Products/LABScreen Single Antigen Products.’’ The
single recombinant HLA-Ia in beadset (cat. #LS1A04, lot 007) in-
cludes 31 HLA-A, 50 HLA-B, and 16 HLA-Cw antigens, together
with in-built control beads, coated with human IgG (considered
positive control) or serum albumin (human or bovine) (negative
control).
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Monospecific HLA-E mAbs
Since the commercial anti-HLA-E mAbs, particularly
those most commonly used on human cancer tissues such as
MEM-E/02 and 3D12 (Table 5), do not meet the critical re-
quirement of monospecificity of the mAb, they may not be
considered reliable for specific immunorecognition of HLA-
E on human cancer tissues. An imminent need is recognized
to generate anti-HLA-E mAbs that can bind only to amino
acid sequences (epitopes) unique or specific for HLA-E and
to revalidate the expression of HLA-E on the cell surface of
cancer cells. Therefore, we have generated(54) several hy-
bridoma clones (n = 258) secreting anti-HLA-E mAbs using
recombinant heavy chains of the two different alleles of
HLA-E, namely HLA-EG107 and HLA-ER107. The glycine
(G) at position 107 is also seen with HLA-F, HLA-G, and
several other HLA-Ia alleles,(54) whereas arginine 107 is
extremely rare among HLA-I, with two exceptions, HLA-
A*01:01:01:02N and HLA-B*15:30. These mAbs were in-
vestigated for their specific affinity for HLA-E by measuring
their MFI in Luminex SAB assays using beads coated with 31
HLA-A, 50 HLA-B, 16 HLA-Cs, one HLA-G, and one HLA-
F antigen. Based on the analysis of the affinity of the anti-
bodies to HLA-Ia and HLA-Ib molecules, the mAbs were
categorized into eight groups as defined in Table 7. Group 1
of the eight groups constitutes mAbs that do not react with
HLA class-Ia alleles or with HLA-F and HLA-G. However,
they reacted to both HLA-EG and HLA-ER. The MFI of the
isotypes of group 1 is compared to assess the potential
strength of the mAbs (Fig. 3). The number of clones secreting
the mAbs (MFI ‡1000) in general and the monospecific
mAbs (MFI >1000) were much higher with HLA-ER107
(12 per mouse) than with HLA-EG107 (8 per mouse). The
most common isotype is IgG1. Several clones showed re-
markable proliferation in culture. The culture supernatants of
five of these clones (TFL-033, TFL-034, TFL-073, TFL-074,
and TFL-145) were purified using Protein-G columns tested
for antibody titers (Table 8).(54) TFL-033 was selected for
analysis of both ascites and culture supernatants. The titri-
metric profile of TFL-033 is shown in Figure 4.
Immunodiagnostic potential of a monospecific
anti-HLA-E mAb
The purified fraction of the TFL mAbs was used for com-
parative staining with MEM-E/02 on tissues of human gastric
cancer(71) and melanoma.(54) As noted earlier, HLA-E without a
leader peptide in the grove does not give stability to the a-heavy
chain/b2m heterodimer. However, as noted in our report,(54) of
the eight groups of mAbs, only one group is truly specific for
HLA-E, whereas others bind to epitopes shared with other HLA
loci, such as HLA-A, HLA-B, HLA-Cw, HLA-F, and HLA-G.
The mAb TFL-033-specific epitopes occur in a1 helix (which
form the groove) and at adjacent naturally exposed domain on
the helices, as illustrated in Table 9 and Figure 1A and B. The
mAb TFL-033 binding to HLA-E coated on SABs was tested
using such HLA-E monospecific peptides in a dosimetric
manner, and the results are illustrated in detail in a figure [fig. 5
in Ravindranath et al.(54)]. The dosimetric inhibition of puri-
fied culture supernatants of TFL-033 was examined with two
HLA-E-restricted peptides, 65RSARDTA71 and 143SEQKSN-
DASE152, at concentrations ranging from 4.4 to 0.27 mg/well.
Although both peptides showed inhibition, the a2 helical pep-
tide SEQKSNDASE showed higher inhibition than the other
peptide. These findings suggest that TFL-033 has better speci-
ficity for recognition of intact trimeric HLA-E than most of the
Table 6. Anti-HLA-E mAbs Reported To Be ‘‘Specific’’ for HLA-E (MEM-E/02 and 3D12) Cross-React
with Several HLA-Ia Molecules
HLA alleles MEM-E/02 3D12 HLA alleles MEM-E/02 3D12 HLA alleles MEM-E/02 3D12
A*1101 (A11) 5171 2372 B*1510 (B71) 1566 B*5101 (B51) 3518
A*2402 (A24) 2072 B*1511 (B75) 4917 B*5102 (B51) 1915
A*2403 (A24) 1034 B*1513 (B77) 3738 B*5201 (B52) 4137
A*2601 (A26) 2873 B*1516 (B63) 1451 B*5301 (B53) 6999 2960
A*2901 (A29) 1319 B*1801 (B18) 2996 B*5401 (B54) 3784
A*3001 (A30) 1013 B*2708 (B27) 1012 B*5501 (B55) 3980
A*3002 (A30) 1272 B*3501 (B35) 2219 B*5601 (B56) 2014
A*3203 (A32) 1204 B*3701 (B37) 7514 B*5701 (B57) 1724
A*3301 (A33) 1575 B*3801 (B38) 1325 B*5703 (B57) 2193 1032
A*3301 (A33) 1561 B*4001 (B60) 4912 1328 B*5801 (B58) 5683 3126
A*3401 (A34) 1950 B*4002 (B61) 2771 B*5901 (B59) 5112 1303
A*4301 (A43) 1010 B*4006 (B61) 9540 4899 B*7301 (B73) 2255
A*8001 (A80) 1161 B*4101 (B41) 4040 B*7801 (B78) 2947
B*0801 (B08) 1858 B*4402 (B44) 5330 B*8101 (B81) 1898
B*1301 (B13) 5811 1720 B*4403 (B44) 4010 1011 B*8201 (B82) 5700
B*1302 (B13) 4699 1118 B*4501 (B45) 1691
B*1401 (B64) 5653 1677 B*4601 (B46) 2652
B*1402 (B65) 2624 B*4701 (B47) 2684 Both mAbs failed to react
B*1502 (B75) 2675 B*4801 (B48) 6294 With iBeads containing only
B*1503 (B72) 5619 B*4901 (B49) 1388 With b2aHC (MFI <1000).
The mAbs were diluted 1/100. Only those alleles with MFI above >1000 are presented. The mAbs were tested on Luminex SABs assay
using regular LABSCreen beadsets (Lot-7) and with iBeads. The regular beadsets are coated with both b2m-associated, peptide–associated,
or peptide-free heavy chain (b2aHC) with admixture of b2m-free heavy chains of HLA (b2fHC).(63)
b2m, b2-microglobulin; MFI, mean fluorescent intensity; SABs, single antigen beads.
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polyreactive commercial mAbs, which bind to b2m-free HLA-
E. That is one of the reasons why MEM-E/02 did not bind to
iBeads (the regular LABSCreen beadset enzymatically treated
to eliminate monomeric and dimeric variants of HLA-I) but
bound only to the regular LABScreen beads. Since human
cancer cells can express both intact trimeric HLA and b2m-free
HLA, there is a need to distinguish the different phenotypic
expression of HLA-E on the surface of tumor lesions. Because
of the unique peptide-binding affinities of TFL-033 and MEM-
E/02, we used both mAbs to study this aspect in gastric can-
cer(71) and melanoma.(54) Only TFL-033 stained the cytoplasm
of normal mucosa (Fig. 5) diffusely. The incidence and in-
tensity of staining of the cell surface in early stages, poorly
or undifferentiated and non-nodal lesions by TFL-033 are
markedly higher than the staining by MEM-E/02. Of note,
however, MEM-E/02 stained terminal stages of adenocar-
cinoma and lymph node metastatic lesions intensely, either
owing to increased expression of b2m-free HLA-E with
tumor progression or owing to expression of other b2m-free
HLA-Ia molecules. Similar comparative observations made
on human melanoma tissues(54) validate the hypothesis that
monospecific anti-HLA-E mAbs reveal the presence of intact
FIG. 2. Structural variants of HLA class-I molecules. (A) Diagrammatic representation of an intact, native, and trimeric
HLA-I molecules with a1, a2, and a3 helices of the heavy chain dimerized with b2m with the presence of a peptide (star) in
the grove. The n-terminal end is extended into a bilayered lipid membrane. (B) Same as (A) but without b2m and peptide,
called a monomeric variant, also known as open conformer. (C) Structure of an intact HLA without peptide but with b2m
shown in blue. The amino acid shown in yellow is cryptic in the presence of b2m but gets exposed for immune recognition
without b2m. The amino acid sequence in the yellow regions is shared by almost all HLA class-I molecules (Table 2). The
monospecific mAb TFL-033 does not bind to the shared amino acid sequences. (D) The exact location, position, and
configuration of the amino acid sequence of the shared epitopes, 115QFAYDGKDY123 and 137DTAAQI,142 recognized by
the polyreactive mAb MEM-E/02 and all the anti-HLA-E mAbs included in group 8 category of mAbs are listed in Table 7.
The antibody epitope prediction formulae(62) support the contention that the epitope for MEM-E/02 and other MEM series is
a discontinuous sequence emerging from six to seven amino acid sequences separated by a long peptide sequence of the
heavy chain of HLA-E molecule.
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Table 7. HLA-E Heavy Chain Monomer, Upon Immunization in a Mouse Model, Elicits Eight Different
Groups of Anti-HLA-E Antibodies; However, Only Group 1 Befits the Definition of HLA-E-Specific
Monoclonal Antibody Because of Its Monospecificity
Classification of the anti-HLA-E mAbs generated at TFL using heavy chain of HLA-E
Anti-HLA mAbs Classical HLA (HLA-Ia) Nonclassical HLA (HLA-Ib)
Characteristics of
the groups of mAbsAlleles -> A B Cw E F G
Group 1 0 0 0 + 0 0 HLA-E monospecific
Group 2 0 0 0 + + 0 HLA-F cross-reactive
Group 3 0 0 0 + 0 + HLA-G cross-reactive
Group 4 0 0 0 + + + HLA-Ib specific
Group 5 + + + + 0 0 HLA-Ia polyreactive
Group 6 + + + + + 0 HLA-Ia/F polyreactive
Group 7 + + + + 0 + HLA-Ia/G polyreactive
Group 8 + + + + + + HLA class-I specific
The monospecific monoclonal HLA-E antibodies recognize none of the other HLA-Ia or Ib molecules. TFL refers to Terasaki Foundation
Laboratory in Los Angeles, where the antibodies were generated and characterized. The mAbs were monitored in Luminex SABs assay
using regular LABSCreen beadsets.
FIG. 3. Several hybridoma clones secreting monospecific mAbs were generated by immunizing the heavy chains of either
HLA-ER107 or HLA-EG107. The number of clones secreting the mAbs in general and the monospecific mAbs in particular
were much higher with HLA-ER107 than with HLA-EG107. The most common isotype seems to be IgG1. The MFI of the
culture supernatants as well the MFI of IgG isotypes is indicated in the figure. For detailed investigation, we have used TFL-
033. Ig, immunoglobulin; MFI, mean fluorescent intensity.
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trimeric native HLA-E than the commercial polyreactive non-
specific HLA-E mAbs.
Potential of monospecific anti-HLA-E mAb to avert
CD94/NKG2A interaction
The binding domain of the monospecific anti-HLA-E
mAb (e.g., TFL-033) and CD94 and NKG2A on the a1 and
a2 helices of HLA-E is the same. Both TFL-003 and the
CD94/NKG2A heterodimer share some of the specific
amino acids. However, we have not done peptide inhibition
studies on all the monospecific anti-HLA-E mAbs. It is
reasonable to infer that all of them may bind to HLA-E-
specific epitopes, which could exist on the a1 and a2 helices
of HLA =E. Possibly some mAbs may share more amino
acids in the binding domain with the NK-inhibitory recep-
tors, CD94-NKG2A, that react with HLA-E-specific epi-
topes on the a1 and a2 helices. Figure 1A illustrates the
exact amino acid (in box) and its location in the epitope in
the a1 helix, with either TFL-033 or CD94. Figure 1B
documents the exact amino acid (in box) and its location in
the epitope in the a2 helix that reacts with both TFL-033
and NKG2A. The nature of the interaction of CD94 or
NKG2A with their respective binding domains on the he-
lices is further clarified in Figure 1A and B as well as in
Table 4. Two critical issues should be addressed in this
context. CD94 or NKG2A bind to more than one amino acid
in their binding domain, but TFL-033 binds to only one of
those amino acids recognized by CD94 or NKG2A. Can
such binding to a single amino acid in each helix by TFL-
033 suffice to block the interaction of CD94 or NKG2A? It
should be noted that for peptide inhibition studies on TFL-
033, we have employed only the amino acids specific for
HLA-E found on each helix. We did not test the whole
amino acid sequence recognized by CD94 or NKG2A.
Probably it would have provided better inhibition of TFL-
033 binding to HLA-E on beads. Second, if a mAb binds to
that epitope, it is sure to create stearic hindrance to block the
binding of CD94 and NKG2A. Possibly other monospecific
mAbs (n = 24) may differ in their efficacy to block binding
of CD04/NKG2A binding based on the amino acid se-
quences recognized by the mAbs. Examining the nature of
amino acids that are recognized by TFL-033, it may be
noted in Figure 1A that Arginine [R] at position-65 con-
stitutes the part of the epitope recognized by mAb TFL-033.
The interaction of CD94 with R-65 involves to hydrogen
bonding and three van der Waal forces (see Table 4 for
details). Monospecific mAb binding can cause hindrance
for this powerful interaction between R65 and CD94.
Similarly, serine [S] at position 152 recognized by the
mAb involves both H bonding and van der Waal forces of
interaction between NKG2A and S-152. However, it may be
that the molecular size and configuration of the IgG1 mAbs
that have spread and bound on the helices of HLA-E are
sufficient to prevent the interaction between HLA-E and the
inhibitory receptors. On blocking the binding of the inhibi-
tory receptors on NK/CD8+ T cells, the antitumor cytotoxic
functions of these immune cells are restored.
Another important issue is whether TFL-033 is capable of
binding to the epitopes on the two helices when a peptide is
present in the grove. The fact that CD94 and NKG2A involve
in a variety of H bonding with salt linkage and multiple van
der Waal force bindings with a single amino acid (see Table 4
for details) even in the presence of a peptide in the grove
suggests that TFL-033 would also bind. As indicated in
Figure 1A and B, the mAb binding sites are exposed at the
periphery of grove peptide binding sites.
Therefore, a humanized or human monospecific anti-
HLA-E mAb mimicking TFL-033 is bound to be a valuable
agent for passive immunotherapy of human cancers. It is
well known that the therapy benefits not all of the patients
receiving the current NK immunotherapy protocols. Failure
of patients to respond to NK therapy could be due to the
level of expression of HLA-E on the tumor cell surface. If
highly expressed, NK cells may be ineffective. The report
provides hope that a combinational therapy admixed with
anti-HLA-E monospecific mAb can be beneficial for these
patients.
Monospecific Anti-HLA-E mAbs Promotes
Proliferation of CD81 T Cells
The monospecific anti-HLA-E mAbs had the potential to
augment the proliferation of nonactivated and activated
CD3+/CD8+ cytotoxic T cells and CD3-/CD8+ NK cells or
NKT cells.(54) Almost all monospecific mAbs augmented the
Table 8. Titers of Protein-G Purified Culture











Titer of the mAbs measured after serial dilution of the immu-
nogen used is the heavy chain of HLA-E.
FIG. 4. Titration of ascites and culture supernatant of the
anti-HLA-ER mAb TFL-033 (IgG1). ER, endoplasmic re-
ticulum.
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Table 9. Comparison of the HLA-E Monospecific Amino Acid Sequences (Epitopes) of Three Epitopes
(One 6-mer [#1], One 9-mer [#2], and One 5-mer [#3])
HLA-E restricted peptides (#1) and (#3)
HLA-Ib alleles
Amino acid positions at a1 heavy chain of HLA
Peptide (#1) Peptide (#3)
65 66 67 68 69 70 180 181 182 183 184
E*01010101 R S A R D T L H L E P
G*01010101 R N T K A H Q R A D P
F*01010101 G Y A K A N Q R A D P
A*110101 R N V K A O Q R T D P
B*1401 Q I C K T N Q R A D P
B*350101 Q I F K T N Q R A D P
B*40060101 Q I S K T N Q R A D P
B*530101 Q I F K T N Q R A D P
B*5801 R N M K A S Q R A D P
Cw*050101 Q K Y K R Q Q R A E H
Cw*080101 Q K Y K R Q Q R A E H
Cw*1802 Q K Y K R Q Q R A E H
Qa-1 W K A R D M Q R S E P
HLA-Ib alleles
Amino acid positions at a1 heavy chain of HLA
Peptide (#2)
143 144 145 146 147 148 149 150 151
E*01010101 S E Q K S N D A S
G*01010101 S K R K C E A A N
F*01010101 T Q R F Y E A E E
A*110101 T K R K W E A A H
B*1401 T Q R K W E A A R
B*350101 T Q R K W E A A R
B*40060101 T Q R K W E A A R
B*530101 T Q R K W E A A R
B*5801 T Q R K W E A A R
Cw*050101 T Q R K W E A A R
Cw*080101 T Q R K W E A A R
Cw*1802 T Q R K W E A A R
Qa-1 S K R K S E A V D
HLA-E restricted peptide (#1)
HLA-Ib alleles 180 181 182 183 184
E*01010101 R S A R D
G*01010101 R N T K A
F*01010101 G Y A K A
A*110101 R N V K A
B*1401 Q I C K T
B*350101 Q I F K T
B*40060101 Q I S K T
B*530101 Q I F K T
B*5801 R N M K A
Cw*050101 Q K Y K R
Cw*080101 Q K Y K R
Cw*1802 Q K Y K R
Qa-1 W K A R D
Since each locus has >1000 alleles, due to space constraints, few alleles for each locus were selected. Qa-I, a murine equivalent of hu
HLA-E is also compared. Peptide #1 and peptide #2 were selected for diametric inhibition of one of the monospecific mAbs [TFL-033, see
fig. 5 in Ravindranath et al.(54)]. The term monospecificity implies the binding of the mAbs to a unique epitope of HLA-E (Table 4).
The bold letters of amino acids of alleles other than HLA-E*01010101 indicate the corresponding position of the amino acids found in
HLA-E. The lack of repetition of the entire sequence of amino acids found in HLA-E establish that the amino acid sequence is HLA-E
restricted.
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proliferation of phytohemagglutinin (PHA)-untreated T
lymphoblasts (TFL-033s at 1/30 ( p < 0.02) and 1/150
( p = 0.001), TFL-034 at 1/10 ( p = 0.005) and 1/50
( p = 0.002), TFL-073 at 1/50 ( p = 0.001), TFL-074 at 1/10
( p = 0.006) (Table 10). The specific increase of ‘‘PHA-
untreated’’ T lymphoblasts points out the potential of the
monospecific anti-HLA-E mAbs in augmenting CD8+ T
lymphoblasts. In addition, a significant increase in the blas-
togenesis of CD8+ T lymphoblasts was observed among the
PHA-treated T lymphoblasts with TFL-033 at 1/30 ( p< 0.02)
and 1/150 ( p = 0.003), with TFL-034 at 1/50 ( p< 0.01), and
with TFL-145 at 1/100 ( p= 0.05). None of the other CD3+ T
cells (CD4+/CD8-, CD4-/CD8-, and CD4+/Cd8+) PHA un-
treated or PHA treated showed any change in the number of
lymphoblasts. We have also used a polyreactive anti-HLA-E
mAb TFL-007 as control, decreasing the population of un-
treated CD3+ and CD8+ T lymphoblasts (Table 10). This
unique property of augmenting the number of CD8+ T lym-
phocytes and not other lymphocytes (Table 10) by mono-
specific but not by polyreactive anti-HLA-E mAbs strongly
clarifies the potential of the monospecific anti-HLA-E mAbs
for passive immunotherapy of cancer. Immunodiagnostic
observations and peptide inhibition studies reported earlier
point out that monospecific anti-HLA-E TFL mAbs are in-
deed capable of binding to HLA-E molecules expressed on
the CD8+ T and NK cells. HLA-E is a component of un-
specified HLA class-I antigens earlier identified at low levels
on inactivated CD8+ cells and upregulated(72,73) or heavily
clustered(74) in activated (by PHA or IFNg) CD8+ cells. Both
blastic transformation and proliferation of immune cells in-
duces transient expression of cell-surface molecules. These
molecules include IL-2R, Fc receptors for IgG (FcgRI/CD64,
FcgRII/ CD32 and FcgRIII/CD16, IgE (FceRII)/CD23), in-
sulin receptors; insulin-like growth factor 1R and IL-2R,
alpha-fetoprotein and transferrin receptors, a non-disulphide-
linked heterodimer of polypeptide chains 33 kDa and 38 kDa
called ‘Me14/D12’, MICA, and HLA class II antigens HLA-
DR, -DP and -DQ [for detailed information and refer-
ences(75)]. Most importantly, over-expression of b2m-free
heavy chains of HLA class I are documented(76–78)). It is
anticipated that the binding of the monospecific anti-HLA-E
mAb onto a1 and a2 helices of the overexpressed and clus-
tered open conformers of HLA-E(74) in activated normal
human CD8+ T and NKT cells may induce phosphorylation,
promoting proliferation of both nonactivated and PHA-
activated CD8+ T and NKT cells. A model illustrating the
hypothesis is presented in our previous report.(54) Since NKT
cells are devoid of CD3 molecules, it is envisaged that the
TFL mAb-mediated activation of CD8+ T cells and NKT
cells may be independent of CD3 molecules or may involve
different cell surface receptors.
Conclusions
HLA-E is one of the MHC class-I antigens with struc-
tural configuration identical to most of the other classical
HLA-Ia and nonclassical HLA-Ib molecules. Using poly-
reactive anti-HLA-E mAbs, enumerable studies suggest
overexpression of HLE-E on the cell surface of several
human cancers. We have confirmed the overexpression
of HLA-E on the cell surface of gastric cancers and mel-
anoma, using monospecific anti-HLA-E mAbs.(54,71)
Tumor-associated HLA-E, upon binding to the inhibitory
receptors (CD94/NKG2A) on NK cells or cytotoxic T cells
(CD8+), inactivates the ability of such cells to kill tumor
cells. Possibly for this reason, the efficacy or outcome of
NK and CD8+ T cell-mediated cancer treatment is not al-
ways as anticipated. We have developed two categories of
mouse HLA-E mAbs, monospecific and polyreactive HLA-
E mAbs.(54) Monospecific HLA-E mAbs bind to HLA-E
only, but not to any other HLA-Ia or HLA-Ib molecules. In
contrast, polyreactive HLA-E mAbs cross react with three
or more of the other loci of HLA class-I, namely HLA-A,
HLA-B, HLA-C, HLA-F, and HLA-G, which is similar to
commercially available mAbs (such as MEM-E0/2, MEM-
E0/6, MEM-E0/7, MEM-E0/8 and 3D12), Therefore, the
monospecific anti-HLA-E mAbs are better able to confirm
specific HLA-E expression on tumor cells and biopsies
obtained from cancer patients. Furthermore, peptides from
the amino acid sequences located on the a1 and a2 helices
of HLA-E specifically inhibited the binding of the mono-
specific mAbs. Interestingly, the same sequences are also
associated with the interaction of HLA-E with the inhibi-
tory receptors (NKG2A and CD94) of NK and CD8+ cells.
FIG. 5. Comparative staining of gastric adenocarcinoma
and diffuse carcinoma with trimeric HLA-E reactive
monospecific mAb TFL-033 and b2m-free heavy chain of
HLA-E and HLA-I polyreactive mAb MEM-E/02. Please
note that intense staining or higher incidence of staining
with MEM-E/02 does not imply it is due to intact, trimeric,
or dimeric HLA-E but due to the monomeric heavy chain of
HLA-I including HLA-E. In adenocarcinoma, MEM-E/02
stained 12 of 30 tissue samples (40%) and the incidence is
higher than that of TFL-033 (27%–30%). In diffuse carci-
noma, TFL-033 stained 18 of 40 tissue samples (45%). The
incidence is higher than that of MEM-E/02 (23%). The
node-negative was significantly more positive staining with
TFL-033 than with the node-positive. Metastatic cancer
included peritoneal (n = 5), liver (n = 3), ovarian (n= 5), and
lymph node (n= 27) metastases. With the mAb MEM-E/02,
21 of the 40 metastatic carcinomas stained intensely (53%),
higher than that of TFL-033 (38%–40%). With lymph node
metastasis, the incidence of staining by TFL-033 was 40%,
whereas that of MEM-E/02 is 56.6%. [Source: Sasaki
et al.(71)].





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Since both the monospecific mAbs such as TFL-033 and in-
hibitory receptors NKG2A/CD94 on NK and cytotoxic T cells
bind to the same sequence of the peptides located in the HLA-
E a1 and a2 helices, these HLA-E-specific mAbs may have the
potential to block the inhibitory pathway responsible for the
poor outcome of the NK and CD8+ T cell-based cytotoxic
killing of cancer cells in some cases. Furthermore, these anti-
HLA-E monospecific but not polyreactive mAbs (such as
TFL-007) have the potential to stimulate the blastogenesis and
proliferation of the cytotoxic CD8+ T cells.(54) Therefore, the
anti-HLA-E monospecific HLA-E mAbs have dual antitumor
potential, both to release NK and CD8+ T cells from their
inactive state caused by binding of CD94.NKG2A with HLA-
E and to simultaneously augment proliferation of the cytotoxic
CD3+/CD4-/CD8+ T lymphocytes.
Thus, the monospecific anti-HLA-E mAbs can enhance
the immune cell-based therapies paving the way for a better
clinical benefit. In addition, these monospecific anti-HLA-E
mAbs may also represent a novel prognostic tool in pa-
tients with GI tumors or malignant melanoma and other
metastasized cancers who plan to undergo immune cell
(NK/NKT/CD8+ T cell)-based therapies by identifying which
tumors/patients are most likely to respond. Preclinical and
clinical trials are required to define the proper role of this
technology in the prognostication and treatment of these
common cancers. In principle, we suggest that anticancer NK
immunotherapy requires determination of the degree of ex-
pression of HLA-E on patients’ primary or metastatic tumors,
with higher expression indicating those most likely to re-
spond to monospecific anti-HLA-E mAb enhancement of
cytotoxicity. Furthermore, tumor biopsies can be monitored
before and during the course of therapy using these mono-
specific HLA-E mAbs.
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